News

Your Spring 2020 Newsletter is Here!

Your copy of the Spring 2020 Newsletter from the MPN Research Foundation is now available

MPNRF Newsletter Survey

With this survey, MPNRF wants to learn more about what kind of information you want to see from us and how you want to receive it.

MPN Patients and COVID-19

Dr. Robyn Scherber answers questions she's received from patients regarding Covid-19 or Coronavirus.

Dr. Mesa offers guidance to MPN Patients about the Coronavirus

Dr. Ruben Mesa, Director, Mays Cancer Center, UT Health San Antonio, MD Anderson, offers guidance for patients with MPNs in dealing with the Covid-19

Corona virus and Interferon

There is no current data about the forms of Interferon taken by those with MPN has an impact on Corona Virus. Please consult your doctor with any questions.

CTI Biopharma Granted Fast Track Designation for Pacritinib in the treatment of Myelofibrosis

CTI Biopharma has been granted Fast Track Designation by the U.S. Food and Drug Administration (FDA) for the development of Pacritinib in the treatment of Myelofibrosis.

MPNs Update - Spring 2020

Dr. Ruben Mesa and Dr. Robyn Scherber hematologists from the Mays Cancer Center discuss the latest updates in new treatments for MPNs

Imago BioSciences Granted Fast Track Designation for IMG-7289 in Essential Thrombocythemia

Imago BioSciences announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of IMG-7289 (bomedemstat) for the treatment of Essential Thrombocythemia.

January New Donor Challenge

An anonymous donor has come forward and offered to MATCH all gifts made to the MPN Research Foundation by NEW donors all through January!

2019 ASH Meeting Report

John Crispino PhD, MBA and Rick Winneker, PhD reports on MPN updates from the 2019 ASH Meeting.

New Clinical Trial Available Myelofibrosis Patients

Actuate Therapeutics Inc. is recruiting patients for Actuate 1901: 9-ING-41, a phase 2 study that will study its efficacy in patients with advanced myelofibrosis.

Research into rare blood cancers called myeloproliferative neoplasms goes global

MPN advocacy organizations are working together across borders to ensure that people living with polycythemia vera, essential thrombocythemia and myelofibrosis will have their treatment needs met by investing in research.

Sierra Oncology Launches the MOMENTUM Phase 3 Clinical Trial for Patients with Myelofibrosis

Sierra Oncology announced today that it has launched the Phase 3 MOMENTUM clinical trial for Myelofibrosis patients

Call for MPN drug to be approved in Australia

"There's actually an even longer-acting version of the drug, an ultra-long-acting version, which has been approved in Europe but not Australia, and we'd like to see that approved here."